• Version
• Download 150
• File Size 0.00 KB
• File Count 1
• Create Date May 16, 2024
• Last Updated May 16, 2024

A retrospective multicentre audit of outcome among patients with Anaplastic Lymphoma Kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with Crizotinib (CRZ) in England

From BTOG 2017: by Kent Yip (Cambridge), Presentation of a multicentre study of outcomes amongst ALK +ve NSCLC patients treated with Crizotinib

Attached Files

1 file

A retrospective multicentre audit of outcome among patients with Anaplastic Lymphoma Kinase (ALK) g

0 KB

Download